Form 4: Amarin Director Oliver O'Connor Reports RSU Vesting

Director Oliver O'Connor acquired 838 American Depositary Shares via RSU vesting and withheld 438 shares for tax obligations.

Summary

• Director Oliver O'Connor exercised 838 Restricted Stock Units (RSUs) on April 18, 2026.
• The transaction resulted in a net increase of 400 shares after 438 shares were withheld by the company to satisfy tax liabilities.
• The withholding was executed at a price of $14.98 per share.
• Following these transactions, the director holds 801 American Depositary Shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard administrative equity vesting rather than a discretionary market trade.

Positives

• The transaction reflects the scheduled vesting of equity compensation, aligning director interests with long-term shareholder value.

Negatives

• The transaction involved a mandatory tax withholding, which is a standard administrative process rather than a market-driven event.

Risks

• The company remains subject to volatility in the pharmaceutical sector and potential impacts from the previously implemented ADS ratio change.

Future Outlook

The remaining RSUs from the 2024 grant are scheduled to vest on April 18, 2027.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of equity compensation vesting, common among pharmaceutical companies utilizing stock-based incentives to retain board members.

Comparison to Industry Standards

• The use of RSU vesting and tax withholding is standard practice for executive and director compensation across the biotechnology and pharmaceutical industries.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine equity compensation event.

Next Steps

• Final vesting of the remaining RSU installment scheduled for April 18, 2027.

Key Dates

Keywords

Amarin, AMRN, Form 4, Insider Trading, Restricted Stock Units, Equity Compensation